NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth…
NeuroPace Inc.March 7, 2024
First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial…
NeuroPace Inc.December 5, 2023
- Upgraded nSight Platform Improves Clinicians’ Ability to Track, Review and Evaluate Patient Data - - ‘Simple Set Programming’ Enables Complete Programming Set Transfer Directly…
NeuroPace Inc.October 20, 2023
First patient receives brain-responsive neuromodulation for LGS, a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif., November 30, 2022--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage…
NeuroPace Inc.November 30, 2022
Groundbreaking NAUTILUS study will evaluate the safety and effectiveness of the RNS System to treat generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW,…
NeuroPace Inc.October 11, 2022
NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS® System in Adolescents
RESPONSE Study first to evaluate the effectiveness of brain-responsive neuromodulation to treat focal epilepsy in patients 12 through 17 MOUNTAIN VIEW, Calif. — May 4,…
NeuroPace Inc.May 4, 2022
IDE study will be first to evaluate the effectiveness of brain-responsive neuromodulation to treat primary generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW,…
NeuroPace Inc.November 10, 2021
New Online Physician Portal Integrates RNS System’s EEG Data with Patient Seizure Diary App to Help Doctors Provide More Comprehensive, Data-Driven Care for Epilepsy Patients…
NeuroPace Inc.August 4, 2021
Feasibility IDE study will be the first to evaluate responsive neuromodulation for a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif. — June 30, 2021…
NeuroPace Inc.June 30, 2021
